Articles By Rob Wright, Chief Editor 2011-2021
-
![Amsterdam City]( "From Utrecht To Amsterdam — Day 3 Of The Netherlands' Biopharma Press Tour — Part 2")
From Utrecht To Amsterdam — Day 3 Of The Netherlands' Biopharma Press Tour — Part 22/4/2019The Netherlands’ biopharma press tour concludes in Amsterdam with presentations (e.g., AIMM Therapeutics) and guided tours of the O2 building and the National Screening Laboratory (NSS) for Sanquin.
-
![covers-450x300]( "Beyond The Printed Page Highlights")
Beyond The Printed Page Highlights2/1/2019A few of our favorite Beyond The Printed Page articles from 2018.
-
![Rob Wright_2017_450x300]( "Trial By Media — Another Cost For Biopharma To Calculate?")
Trial By Media — Another Cost For Biopharma To Calculate?2/1/2019How the interview with J&J’s Joaquin Duato originated over a year ago, and how the company is dealing with a recent negative article in the media.
-
![Joaquin Duato J&J photo sitting_450x300]( "A Look Inside J&J's Partnering & Innovation-Building Model")
A Look Inside J&J's Partnering & Innovation-Building Model2/1/2019Joaquin Duato, vice chairman of J&J’s executive committee, discusses how the company’s partnering and innovation-building model has evolved — and why.
-
![From Utrecht To Amsterdam — Day 3]( "From Utrecht To Amsterdam — Day 3 Of The Netherlands' Biopharma Press Tour — Part 1")
From Utrecht To Amsterdam — Day 3 Of The Netherlands' Biopharma Press Tour — Part 11/30/2019Day 3 of the Netherlands’ biopharma press tour begins with presentations at the Utrecht Science Park (USP).
-
![board meeting]( "The Board Meeting West — More Than Just A Pre-JPM Appetizer?")
The Board Meeting West — More Than Just A Pre-JPM Appetizer?1/16/2019Rob Wright provides insight into The Board Meeting West, a life sciences industry event for high-level biopharmaceutical executives serving on corporate boards, or hoping to do so in the near future.
-
![Rob Sage CEO]( "There Is Value To Being At The Center Of The JPM Universe")
There Is Value To Being At The Center Of The JPM Universe1/15/2019Rob Wright provides a bit of his perspective on the 37th Annual J.P. Morgan Healthcare Conference.
-
![Feature_Halozyme_HelenTorley_450x300]( "How Halozyme's First-Time CEO Financed Drug Development")
How Halozyme's First-Time CEO Financed Drug Development1/2/2019“Making sure we had the money for staff and activities to build the business for the long-term was a key initial step,” explains Dr. Helen Torley, CEO of Halozyme Therapeutics.
-
![Rob Wright_2017_450x300]( "Another Year Older, But Are We Another Year Wiser?")
Another Year Older, But Are We Another Year Wiser?1/2/2019What measures should we use to reflect on the 2018 biopharma industry? One metric could be the number of novel drug approvals.
Rob Wright
Rob Wright was chief editor of Life Science Leader magazine from 2011-2021. Prior to joining the publication, he spent nearly 20 years in the pharmaceutical industry. During his industry career, Wright conducted well over 1,000 presentations and roundtable discussions, including the facilitation of FDA-mandated clinical training programs for hundreds of licensed healthcare providers. He has chaired, moderated, and served as a speaker at industry and academic conferences, and served as co-chair for the 2015 and 2018 BIO International conference’s educational planning committee. Wright’s 500+ published articles have appeared in peer-reviewed academic journals, B2B magazines and online publications. He received a B.S. in Business Administration from Indiana University of Pennsylvania, MBA with distinction from Gannon University, and completed his doctoral coursework in marketing at Cleveland State University. He is a member of international business honor societies Sigma Beta Delta and Beta Gamma Sigma. He can be followed on Twitter @RfwrightLSL